VEGFA and polycystic ovary syndrome: GnRHa has emerged as the trigger of choice in PCOS, hyper-responders and donors, as it virtually eliminates or reduces the risk of developing OHSS because of its short half-life (60–120 min), limits the production of vascular endothelial growth factor, the key mediator of OHSS (11, 12).